Metropolis Healthcare Ltd

Stage 3 · Topping · week 1

As of 16 Oct 2026, Metropolis Healthcare is in Stage 3 — topping, where an uptrend loses steam, in its first week (since 13 Oct 2026). It closed at ₹530, 11.9% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.6% of stocks are in Stage 2.

Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. More about the company

₹530.4
+1.41% today
₹11,002 Cr · Mid cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dHospitals & Diagnostic Centres 19.4%-19.4 pts

Pro read

Pro

Our read

Topping — the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is METROPOLIS early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-11.9%
₹421.8 lo₹602.1 hi
11.9% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 1
1w13w26w
Week 1 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
2.2%
200 DMA: ₹518.9 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.70x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↓
MA20 rolling over · -4.4% vs MA50 -1.3%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-8.7%
3M
-2.7%
6M
+12.3%
YTD
+12.4%
1Y
+5.3%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
19.4%
20d Δ
-19.4pp
1M return
-10.4%
3M return
-12.2%
Industry Stage-2 % · last 20 days
Industry has 5 Stage 2 leaders. See Hospitals & Diagnostic Centres Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 23w
S2 34w
S4 18w
S3 16w
S2 19w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S2 6w → S3 4w → S2 23w → S3 2w → S2 34w → S3 8w → S4 18w → S1 10w → S2 11w → S3 16w → S4 11w → S1 4w → S2 19w → S3 1w current
Total tracked: 168 weeks across 15 stage runs.
Scan Membership
Prop Scan
Latest: 2026-09-25
Pullback Hunter
Latest: 2026-08-13
60 appearances in last 60 days. First seen: 2026-07-02.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S3
Wk 1 · Vol 0.70x
2026-10-15S3
Wk 1 · Vol 1.00x
2026-10-14S3
Wk 1 · Vol 1.51x
2026-10-13S32→3
Wk 1 · Vol 1.17x
2026-10-12S2
Wk 18 · Vol 0.53x
2026-10-09S2
Wk 18 · Vol 0.42x
2026-10-08S2
Wk 18 · Vol 0.60x
2026-10-07S2
Wk 18 · Vol 0.45x
2026-10-06S2
Wk 18 · Vol 1.38x
2026-10-05S2
Wk 17 · Vol 1.00x
2026-10-01S2
Wk 17 · Vol 1.73x
2026-09-30S2
Wk 17 · Vol 2.29x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹565.2
200 DMA
₹518.9
52W High
₹602.1
52W Low
₹421.8
5D Low
₹523
Resistance levels (recent highs)
20d High
₹597.5
60d High
₹602.1
120d High
₹602.1
250d High
₹602.1
Next resistance
+12.7%
to 20d High
Ask the Market AI about METROPOLISAsk →
P/E (TTM)
58.3
Forward 35.4
Earnings Growth (YoY)
+73.0%
Revenue +23.0%
ROE
+13.4%
Profit margin +11.5%
Dividend Yield
0.37%
P/B 7.3
About this companyHealth Care· Hospitals & Diagnostic Centres

Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.